Contribute Try STAT+ Today

Good morning, everyone, an welcome to another working week. We hope the weekend respite, which was an extended break on this side of the pond, was relaxing and invigorating, because that oh-so-familiar routine of meetings, calls, and deadlines has just returned. But what can you do? The world keeps spinning. So grab hold of a cup of stimulation or, perhaps, a water bottle to help you keep your balance and dig in to the items of interest we have assembled for you. Hope you ease back in gracefully today and, as always, do keep in touch.

Eleven drug makers, led by Pfizer (PFE) and Novartis (NVS), have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis. The full scope of the Novartis plan, a $500 million investment, is second only to Pfizer, which has allocated $600 million to build gene therapy plants. Drug makers say building their own manufacturing plants is a response to rising costs and delays associated with relying on third-party contract manufacturers, which are also expanding to capitalize on demand.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.